Genmab A/S Stock Falls Wednesday, Underperforms Market

Hargreave Hale AIM VCT Tightens Share Base with Buyback and Cancellation

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease

Biohaven Shares Gain 5% on SK Biopharma Epilepsy Licensing Deal Worth up to $795 Million

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading

Roivant Says JAMA Dermatology Publishes Phase 3 VALOR Data Showing Brepocitinib Improves Dermatomyositis Skin Outcomes

Jama Dermatology Publishes Skin-Specific Outcomes from Phase 3 Valor Trial of Brepocitinib in Dermatomyositis

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

Spyre Therapeutics Down over 12%, on Pace for Largest Percent Decrease Since June 2024

Ligand Targets $150-$250 Million in Annual Investments as Royalty Revenue Tops $225 Million in 2026 Guidance

Agenus: No colorectal cancer recurrences observed at updated follow-up in trial

Agenus Reports no Recurrences in Phase 2 NEST Trial of Botensilimab Plus Balstilimab in Resectable Colon Cancer

Summit Therapeutics’ Ivonescimab Shows Phase III Survival Benefit

Unusually active option classes on open August 26th

Evommune Shares up 1.7% as Needham Starts Coverage

Sunshine Biopharma provides update, outlines plans for oncology project

Gyre Therapeutics unveils capital-efficient global development strategy

Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes